Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059875 | 0.85 | PDE5A (0.62) | PDE5AAURKAPDGFRBPDGFRAPDE2A | |
| SCHEMBL4055464 | 0.85 | AURKA (0.60) | AURKAPARP1 | |
| SCHEMBL4051168 | 0.85 | PDE5A (0.58) | PDE5AAURKAPDGFRBPDGFRAPDE2A | |
| SCHEMBL4053861 | 0.84 | AURKA (0.59) | AURKAPARP1 | |
| SCHEMBL4055971 | 0.83 | AURKA (0.56) | PDE5AAURKAPDGFRBPDGFRAPDE2A | |
| SCHEMBL4057426 | 0.83 | AURKA (0.48) | AURKA | |
| SCHEMBL4061917 | 0.82 | PDE5A (0.55) | PDE5AAURKAPDGFRBPDGFRAPDE2A | |
| SCHEMBL13607908 | 0.81 | PDGFRB (0.50) | PDE5AAURKAPDGFRBPDGFRAPDE10A | |
| SCHEMBL4058101 | 0.81 | AURKA (0.50) | PDE5AAURKAPDGFRBPDGFRAAMY1A | |
| SCHEMBL4054400 | 0.80 | AURKA (0.52) | PDE5AAURKAPDGFRBPDGFRAAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | PDE5A 2762/4885AURKA 247/4885PDGFRB 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.